Aktieanalys

Spago Nanomedical: Phase IIa trial with SpagoPix in endometriosis - Redeye

Redeye Publicerad: 07 Dec 2022 08:25

Redeye comments on Spago resolving to conclude SPAGOPIX-01 and starting a phase IIa trial with SpagoPix/SN132D in endometriosis. We previously viewed a potential SpagoPix deal in 2023e as a significant catalyst and source of non-dilutive funding. However, our suspicion that SPAGOPIX-01 data might not suffice to strike a deal seemingly turned out correct, and we judge a SpagoPix deal is now likely in 2024e. We adjust our estimates and lower our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/867829/spago-nanomedical-phase-iia-trial-with-spagopix-in-endometriosis?utm_source=finwire&utm_medium=RSS

Nyheter om Spago Nanomedical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!